Short Interest Runner: Time to Reconsider Syndax Pharmaceuticals Incorporated (NASDAQ:SNDX) After Less Short Sellers?

November 16, 2016 - By Louis Casey   ·   0 Comments

Short Interest Runner: Time to Reconsider Syndax Pharmaceuticals Incorporated (NASDAQ:SNDX) After Less Short Sellers?

The stock of Syndax Pharmaceuticals Incorporated (NASDAQ:SNDX) registered a decrease of 8.67% in short interest. SNDX’s total short interest was 294,800 shares in November as published by FINRA. Its down 8.67% from 322,800 shares, reported previously. With 95,500 shares average volume, it will take short sellers 3 days to cover their SNDX’s short positions. The short interest to Syndax Pharmaceuticals Incorporated’s float is 3.01%. About 5,357 shares traded hands. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has declined 37.00% since April 14, 2016 and is downtrending. It has underperformed by 41.69% the S&P500.

Syndax Pharmaceuticals, Inc is a clinical stage biopharmaceutical firm focused on developing a pipeline of combination therapies in multiple cancer indications. The company has a market cap of $177.22 million. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It currently has negative earnings. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy.

SNDX Company Profile

Syndax Pharmaceuticals, Inc., incorporated on October 11, 2005, is a clinical stage biopharmaceutical firm focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

More recent Syndax Pharmaceuticals Inc (NASDAQ:SNDX) news were published by: Marketwatch.com which released: “Syndax Pharmaceuticals” on June 19, 2014. Also Quotes.Wsj.com published the news titled: “News Syndax Pharmaceuticals Inc.SNDX” on April 11, 2011. Globenewswire.com‘s news article titled: “Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and …” with publication date: November 10, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>